Supernus Pharmaceuticals reported $-58.37M in Net Income for its fiscal quarter ending in June of 2026.





Net Income Change Date
Abbott USD 920M 8M Sep/2026
ANI Pharmaceuticals USD 35.15M 10.44M Sep/2026
Aurora Cannabis CAD -4.03M 67.07M Jun/2026
Bristol-Myers Squibb USD 2.16B 1.16B Sep/2026
Canopy Growth CAD -14.58M 142.54M Jun/2026
Cara Therapeutics USD -6.8M 1.28M Mar/2026
Corcept Therapeutics USD 124.49M 82.35M Sep/2026
Eisai JPY 11.69B 6.55B Sep/2026
Eli Lilly USD 7.1B 301M Jun/2026
Novo Nordisk DKK 20.99B 5.9B Jun/2026
Perrigo USD -27.5M 102M Sep/2026
Pfizer USD 3.24B 3.49B Sep/2026
Supernus Pharmaceuticals USD -58.37M 56.08M Jun/2026
United Therapeutics USD 258.6M 74.4M Sep/2026
Xeris Pharmaceuticals USD -31.1M 33.34M Jun/2026